Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Revolution Medicines Inc (RVMD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Revolution Med's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.93 -0.55    -2.00%
20/10 - Closed. Currency in USD ( Disclaimer )
After Hours
26.93
+0.03
+0.11%
16:01:20 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US76155X1000 
CUSIP:  76155X100
  • Volume: 261,331
  • Bid/Ask: 25.12 / 36.20
  • Day's Range: 26.77 - 27.94
Revolution Med 26.93 -0.55 -2.00%
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

150

Equity Type

ORD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

Contact Information

Phone +1-415-7663638
Fax 302-6365454

Top Executives

Name Age Since Title
Flavia Borellini 62 2021 Independent Director
Sue Gail Eckhardt 63 2021 Senior Advisor & Scientific Advisory Board Member
Vincent A. Miller 59 2017 Independent Director
Barbara Weber 64 2018 Independent Director
Thilo Schroeder 39 2018 Independent Director
Julian Adams 66 2016 Senior Advisor & Member of Scientific Advisory Board
Trever Bivona - 2016 Senior Advisor & Member of Scientific Advisory Board
Kevan M. Shokat - 2016 Academic Co-Founder & Member of Scientific Advisory Board
Martin D. Burke - - Co-Founder & Chairman of Scientific Advisory Board
Neil A. Exter 63 2019 Independent Director
John Kuriyan - 2016 Senior Advisor & Member of Scientific Advisory Board
Mark A. Goldsmith 59 2014 CEO, President & Chairman
Eric Thomas Schmidt 51 2020 Independent Director
Alexis A. Borisy 49 2014 Lead Independent Director
Elizabeth McKee Anderson 64 2015 Independent Director
Eric M. Gordon - 2016 Senior Advisor & Member of Scientific Advisory Board
Michael A. Fischbach 40 2016 Academic Co-Founder & Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RVMD Comments

Write your thoughts about Revolution Medicines Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
STIJN LIBAERS
STIJN LIBAERS Feb 13, 2020 2:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
STIJN LIBAERS
STIJN LIBAERS Feb 13, 2020 2:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
boy or skip?
John Simmons Simmons
John Simmons Simmons Feb 10, 2020 5:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to entry or not to entry Mr. Ilya ?
Ilya Atomiq
Ilya Atomiq Feb 10, 2020 7:29AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looks good
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email